Q-omics provides the consensus-scored PMS2P9 profile across patient tissues and cancer cell-line models. PMS2P9 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PMS2P9 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, PMS2P9 RNA expression shows 8,139 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight CESC, COAD, and READ as cancer lineages where PMS2P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMS2P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMS2P9 survival associations across molecular data types. PMS2P9 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMS2P9 RNA expression–survival associations across cancer types. High PMS2P9 expression shows unfavorable associations in STAD, KIRC and UCEC, but favorable associations in CESC, SKCM and LUSC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PMS2P9 RNA expression.
This table summarizes PMS2P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PMS2P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMS2P9 shows lower tumor expression in COAD and THCA and higher tumor expression in PAAD, LUSC, LUAD and KIRP. The COAD box plot shows higher PMS2P9 RNA expression in normal versus tumor tissue (log2 FC = −0.201, t-test p = .009).
This table shows molecular features associated with PMS2P9 in patient tissues and cancer cell lines. In patient samples, PMS2P9 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, PMS2P9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
